吉西他滨联合奥沙利铂二线治疗复发难治性卵巢癌的临床疗效观察  

Experimental Study of Gemcitabine-oxaliplatin Combination for Recrudescent or Intractable Ovarian Cancer

作　　者：卢琳[1] 王秀珍[1] 赵清叶[1] 

机构地区：[1]青岛大学医学院第二附属医院肿瘤科,山东青岛266042

出　　处：《潍坊医学院学报》2011年第4期255-256,共2页Acta Academiae Medicinae Weifang

摘　　要：目的 观察吉西他滨联合奥沙利铂治疗复发难治性卵巢癌,临床影像学及肿瘤标志物CA125的变化情况,评价该化疗方案的临床疗效.方法22例复发难治性卵巢癌患者采用吉西他滨联合奥沙利铂方案进行化疗两个周期,化疗前后检测外周血中的CA125,并观察影像学变化情况.结果患者化疗后CA125降低,有统计学意义；影像学上比较肿块退缩情况,取得了较高的有效率.结论 吉西他滨联合奥沙利铂方案二线治疗复发难治性卵巢癌有较好的治疗疗效,副反应可耐受.Objective To observe lhe change of CA125 in the peripheal blood and clinical iconograph＇,, in recrudescent or intrac- able owtrian cancer before and alter chemotherapy of gemcilabine and oxaliplalin, and observe lhe clinical curalive effect of lhe chemothera- py. Methods Twenty-two patients with recrudescent or intractable owu＇ian cancer were treated with chemotherapy of gemcitabine and oxali- platin. The change of CA125 and clinical iconography were checked before and after two period chemotherapy. Results The concentrations of CAI25 were significantly decreased after treatment,there was statistical diterence. There were a ifighly effective rate by comparing the tumour befk）re and after trealment. Conclusion Gemcitabine combine with oxaliplatin are extremely effective for recrudescent or intraclable ovarian cancer, and the side effect is not serious.

关 键 词：吉西他滨 奥沙利铂 卵巢肿瘤 CA125 

分 类 号：R737.31[医药卫生—肿瘤]